Research graph
References from Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase. Local targets link to admitted publications; unresolved targets remain external evidence.
Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator
10.1016/s0021-9258(19)81052-9 · 1982 · External reference
Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator
10.1016/0003-9861(88)90182-8 · 1988 · External reference
The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1
10.1111/j.1538-7836.2007.02422.x · 2007 · External reference
A faster-acting and more potent form of tissue plasminogen activator
10.1073/pnas.91.9.3670 · 1994 · External reference
Platelets synthesize large amounts of active plasminogen activator inhibitor 1
10.1182/blood-2004-04-1439 · 2004 · External reference
Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
10.1161/01.cir.99.23.3050 · 1999 · External reference
Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop
10.1161/01.atv.14.9.1452 · 1994 · External reference
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial
10.1016/s0140-6736(22)01054-6 · 2022 · External reference
Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials
10.1212/wnl.0000000000209903 · 2024 · External reference
Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label, multicenter trials
10.1007/s40256-018-0284-1 · 2018 · External reference
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial
10.1016/s0140-6736(22)02600-9 · 2023 · External reference
Tenecteplase: biochemical and clot lysis activity comparisons
10.3389/fphar.2024.1498116 · 2024 · External reference
Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse(®)) with those of an alleged biosimilar
10.3389/fphar.2014.00007 · 2014 · External reference
Halo fluorescence fibrinolysis test: a novel quantitative assay to evaluate fibrinolysis on established plasma clots
10.1016/j.rpth.2025.102874 · 2025 · External reference
A comparative study of structure, stability and function of sc-tenecteplase in the presence of stabilizing osmolytes
10.1016/j.jbiotec.2018.05.014 · 2018 · External reference
Halo fluorescence fibrinolysis (HoFF) test: a novel quantitative assay to evaluate the fibrinolysis on established plasma clots
10.1016/j.rpth.2025.102874 · 2025 · External reference
A study of proteases and protease-inhibitor complexes in biological fluids
10.1084/jem.148.1.223 · 1978 · External reference
The influence of differentially expressed tissue-type plasminogen activator in experimental autoimmune encephalomyelitis: implications for multiple sclerosis
10.1371/journal.pone.0158653 · 2016 · External reference
Concentration of plasminogen and antiplasmin in plasma and serum
10.1136/jcp.34.9.979 · 1981 · External reference
Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation
10.1111/j.1538-7836.2008.03056.x · 2008 · External reference
Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA
10.1055/s-0038-1647254 · 1990 · External reference
The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage
10.1016/0167-4838(88)90123-9 · 1988 · External reference
Converting tissue-type plasminogen activator into a zymogen
10.1074/jbc.271.46.28749 · 1996 · External reference
Enzymatic properties of the one- and two-chain form of tissue plasminogen activator
10.1016/0049-3848(82)90197-9 · 1982 · External reference
Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?
10.1038/jcbfm.2014.99 · 2014 · External reference
A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen
10.1055/s-0038-1649572 · 1993 · External reference
Making tissue-type plasminogen activator more fibrin specific
10.1093/protein/6.5.529 · 1993 · External reference
High resolution analysis of functional determinants on human tissue-type plasminogen activator
10.1016/s0021-9258(19)67773-2 · 1991 · External reference
A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA)
10.1055/s-0038-1649571 · 1993 · External reference
Involvement of residues 296-299 in the enzymatic activity of tissue-type plasminogen activator
10.1093/protein/5.3.259 · 1992 · External reference
Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays
10.1002/2211-5463.70132 · 2026 · External reference
Tenecteplase reperfusion therapy in acute ischaemic cerebrovascular events-II (TRACE II): rationale and design
10.1136/svn-2021-001074 · 2022 · External reference
Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study
10.1136/svn-2021-000978 · 2022 · External reference
Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy
10.1056/nejmoa2402980 · 2024 · External reference
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial
10.1016/s1474-4422(24)00206-0 · 2024 · External reference
Prospective observational cohort study of tenecteplase: results from the Indian registry in ischemic stroke-tenecteplase
10.1161/jaha.124.036382 · 2024 · External reference
Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator
10.1021/ac100956x · 2010 · External reference
